INDSWFTLAB Intraday Analysis...

INDSWFTLAB Share Price

Open 39.85 Change Price %
High 39.90 1 Day -1.95 -4.96
Low 37.15 1 Week -0.60 -1.58
Close 37.40 1 Month 3.00 8.72
Volume 37035 1 Year -0.05 -0.13
52 Week High 47.90
52 Week Low 31.25
INDSWFTLAB Important Levels
Resistance 2 39.95
Resistance 1 38.90
Pivot 38.15
Support 1 35.90
Support 2 34.85
NSE INDIA Most Active Stocks
UNITECH 7.65 -4.38%
JPASSOCIAT 17.95 2.28%
FORTIS 128.00 -7.71%
RCOM 11.65 0.43%
SBIN 318.45 0.02%
BPL 102.60 12.38%
BPL 102.60 12.38%
BPL 102.60 12.38%
PNB 173.70 0.43%
TV18BRDCST 54.70 -3.61%
More..
NSE INDIA Top Gainers Stocks
KOKUYOCMLN 144.50 19.97%
TFL 18.75 19.81%
RAJRAYON 0.35 16.67%
KESARENT 73.70 15.25%
INDIANCARD 215.60 15.08%
ENERGYDEV 27.50 15.06%
DOLPHINOFF 128.30 13.19%
PRIMESECU 62.35 12.85%
NAKODA 0.45 12.50%
BPL 102.60 12.38%
More..
NSE INDIA Top Losers Stocks
UVSL 0.40 -11.11%
WSI 7.75 -9.88%
MOTOGENFIN 45.15 -9.52%
CHROMATIC 2.85 -9.52%
CELEBRITY 15.80 -9.46%
AUSOMENT 79.30 -9.32%
ELECTHERM 144.80 -9.22%
REPRO 784.40 -9.03%
EMCO 18.50 -8.87%
SURANAIND 3.70 -8.64%
More..

Ind-Swift Laboratories Limited (NSE: INDSWFTLAB)

INDSWFTLAB Technical Analysis 3
As on 12th Dec 2017 INDSWFTLAB Share Price closed @ 37.40 and we RECOMMEND Buy for LONG-TERM with Stoploss of 36.98 & Buy for SHORT-TERM with Stoploss of 34.79 we also expect STOCK to react on Following IMPORTANT LEVELS.
INDSWFTLAB Target for December
1st Target up-side 36.93
2nd Target up-side 38.71
3rd Target up-side 40.49
1st Target down-side 31.87
2nd Target down-side 30.09
3rd Target down-side 28.31
INDSWFTLAB Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 54.65 Sideways
MFI (14) MFI is Above 80 Over Bought
CCI (20) CCI is 71.15 Sideways
WILLIAM %R (14) William %R is -56.50 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 36.24
10 Day Avg Volume Traded -61.07 % Less then 10 Day Average Volume
INDSWFTLAB Other Details
Segment EQ
Market Capital 872314432.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.indswiftlabs.com
INDSWFTLAB Address
INDSWFTLAB
Shivalik Enclave
SCO 850
Manimajra, 160101
India
Phone: 91 17 2273 0503
Fax: 91 17 2273 0504
INDSWFTLAB Latest News
Ind-Swift Labs To Raise Funds From Strategic Investors   DealCurry   - 31st Jul 14
Ind-Swift Lab extends Tuesday's rally   Business Standard   - 23rd Jul 14
SP Tulsian's multibaggers: Rallis India, Ind-Swift Labs   Moneycontrol.com   - 11th Jun 13
Ind-Swift Labs aims to touch Rs 1500cr turnover by 2015   Moneycontrol.com   - 09th Dec 12
Piramal Healthcare in talks to buy Ind-Swift Lab: Report   India Today   - 04th Sep 12
Ind-Swift Labs board approves debt recast plan   Hindu Business Line   - 16th Jul 12
Ind-Swift, Wockhardt launch Atorvastatin tablets in UK   Economic Times   - 16th May 12
Ind-Swift Labs gets USFDA approval for 5 APIs for its Derabassi facility   Moneylife Personal Finance site and magazine   - 10th Apr 12
Expect turnover of Rs 50cr from menthol biz: Ind-Swift Labs   Moneycontrol.com   - 26th Dec 11
Ind-Swift Labs eyes good volumes on exports to Japan   Moneycontrol.com   - 18th Feb 11
Interactive Technical Analysis Chart Ind-Swift Laboratories Limited ( INDSWFTLAB NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ind-Swift Laboratories Limited
INDSWFTLAB Business Profile
Ind-Swift is in the Pharmaceuticals - Bulk Drugs sector. Incorporated in 1995, Chandigarh, India-based Ind-Swift Laboratories (ISL) is a part of the Ind-Swift group. The company is promoted and managed by Ind-Swift in joint venture with Punjab State Industrial Development Corporation. Manufacturing units of ISL are located in Punjab and Jammu. Ind Swift Laboratories, a wholly owned subsidiary of ISL, was incorporated in the USA in Mar. 2004. It manufactures a wide range of solid, liquid, semi liquid forms, capsule, tablets, dry/liquid injectable eye/ear drops, oral solution, and creams/gels. The company`s products include Clarithromycin, Fexofenadine, Clarie granules, Pentazocine, Roxithromycin, Clopidogrel, Azithromycin, and Atorvastatin. Its products are used in the macrolide antibiotic, antiallergy, cardiovascular, diabetology, and antiulcerant therapeutic sector. ISL has emerged as an efficient supplier of bulk-actives in more than 45 countries. The services of the company includes research for active pharmaceuticals intermediaries / advanced intermediates, development of non-infringing processes for promising molecules, process optimization and improvement, contract research, contract manufacturing, etc. The current market capitalisation stands at Rs 28.58 crore.The company has reported a standalone sales of Rs 139.17 crore and a Net Loss of Rs 41.99 crore for the quarter ended Jun 2013. The company management includes S R Mehta - Chairman, N R Munjal - Vice Chairman, Gopal Munjal - Managing Director & CEO, V R Mehta - Joint Managing Director, Himanshu Jain - Director, Rishav Mehta - Director, K M S Nambiar - Director, R S Bedi - Director, H P S Chawla - Director, S K Mathur - Director, S P Sharma - Independent Director, Atul Saxena - Nominee Director. It is listed on the BSE with a BSE Code of 524652 and the NSE with an NSE Code of INDSWFTLTD. Its Registered office is at 781, Industrial Area - II , Chandigarh,Chandigarh - 160002.